EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Scleroderma‐Specific Autoantibodies and Disease Trajectories in Early Systemic Sclerosis: Insights From a Single‐Center Prospective Registry

Marzieh Jamali, Amisha Kaur, Suiyuan Huang, Carleigh Zahn, Erica Mulcaire-Jones, John Varga, Dinesh Khanna

ACR Open Rheumatology · 2026-09 · 8 (9)

DOI: 10.1002/acr2.90142 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACR Open Rheumatology, online erschienen am 15.09.2026. Verfasst von Marzieh Jamali und 6 weiteren Autor:innen. Beteiligte Einrichtung: Scleroderma Program, University of Michigan, Ann Arbor, MI, USA. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Early diffuse cutaneous systemic sclerosis (dcSSc) is associated with substantial disease‐specific mortality. Scleroderma‐specific autoantibodies (SSc‐Ab) may influence disease course, but their prognostic value in very early dcSSc remains unclear. We examined associations between autoantibody profiles and disease trajectories for clinical events in a prospective single‐center cohort.

Methods

We retrospectively analyzed prospectively collected data from a subset of patients enrolled in an early SSc registry between October 2012 and July 2021, including those with early dcSSc or individuals at risk for dcSSc less than two years of their first non‐Raynaud phenomenon (RP) symptom. Participants were classified as anti‐RNA polymerase III antibody positive (RNAP3+), anti‐topoisomerase I antibody positive (Scl70+), or triple‐negative (negative for RNAP3, Scl70, and anticentromere antibody [ACA]).

Results

Among 115 patients with available SSc‐Ab data (median follow‐up, 5.5 years [interquartile range 2.1–7.2]), 42 were RNAP3+, 29 Scl70+, 6 ACA+, and 38 triple‐negative. ACA+ patients were excluded from subgroup analyses because of the small sample size. Of the remaining 109 patients, 17 with prior clinical events at baseline were excluded from time‐to‐event analyses. Among the 92 included patients, 50 (54.3%) experienced one or more new clinical events during follow‐up, including 59.4% of RNAP3+, 57.1% of Scl70+, and 46.9% of triple‐negative patients. Among first new clinical events, RNAP3+ patients had higher frequencies of scleroderma renal crisis (6.3% vs 3.6% in Scl70+ and 0% in triple‐negative), malignancy (35.7% vs 24.1% and 15.8%, respectively), mortality (9.4% vs 3.6% and 0%, respectively), and forced vital capacity decline (15.6% vs 10.7% and 12.5%, respectively), whereas modified Rodnan skin score worsening was most frequent in triple‐negative patients (15.6% vs 10.7% in Scl70+ and 9.4% in RNAP3+).

Conclusion

Scleroderma‐specific autoantibodies in early SSc were associated with distinct baseline clinical phenotypes and showed numerical differences in longitudinal clinical outcomes in this single‐center cohort. image

Autor:innen und Institutionen

  • Scleroderma Program, University of Michigan, Ann Arbor, MI, USA.
  • Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.

Zitieren

APA

Jamali, M., Kaur, A., Huang, S., Zahn, C., Mulcaire-Jones, E., Varga, J., & Khanna, D. (2026). Scleroderma‐Specific Autoantibodies and Disease Trajectories in Early Systemic Sclerosis: Insights From a Single‐Center Prospective Registry. ACR Open Rheumatology, 8(9). https://doi.org/10.1002/acr2.90142

Vancouver

Jamali M, Kaur A, Huang S, Zahn C, Mulcaire-Jones E, Varga J, et al. Scleroderma‐Specific Autoantibodies and Disease Trajectories in Early Systemic Sclerosis: Insights From a Single‐Center Prospective Registry. ACR Open Rheumatology. 2026;8(9). doi:10.1002/acr2.90142

BibTeX
@article{Jamali2026,
  author = {Jamali, Marzieh and Kaur, Amisha and Huang, Suiyuan and Zahn, Carleigh and Mulcaire-Jones, Erica and Varga, John and Khanna, Dinesh},
  title = {Scleroderma‐Specific Autoantibodies and Disease Trajectories in Early Systemic Sclerosis: Insights From a Single‐Center Prospective Registry},
  journal = {ACR Open Rheumatology},
  year = {2026},
  volume = {8},
  number = {9},
  doi = {10.1002/acr2.90142}
}
Kostenlos starten →